Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FXANL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-637
|
|||||
| Synonyms |
ABBV-637
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-EGFR antibody
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
BCL-xL inhibitor
|
Payload Info | ||||
| Therapeutic Target |
Bcl-2-like protein 1 (BCL2L1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Lung cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease control rate (DCR) |
65
73 % |
|||
| Patients Enrolled |
Key eligibility: Adults with solid tumors (Part 1) or EGFR-altered NSCLC (Parts 2-3), measurable disease (RECIST 1.1), ECOG 0-1. Exclusions: cardiac dysfunction (NYHA ≥2 within 6 months), unresolved Grade 2+ toxicities, or (for Part 3) history of ILD/pneumonitis requiring steroids. Requires progression after prior therapies (platinum-based for Part 2, osimertinib for Part 3).
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-637 in 28-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04721015 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors | ||||
| Primary Endpoint |
Primary objectives evaluate safety through AE/SAE incidence (up to 3 years) and efficacy via ORR (confirmed CR/PR per RECIST 1.1 by investigator assessment) in Parts 2 and 3.
|
||||
| Other Endpoint |
Secondary endpoints assess ORR in Part 1 (3 years), DOR (time from CR/PR to progression/death) for ABBV-637 monotherapy (12 months) and combination therapies (20 months), PFS (time to progression/death) and OS (time to death) for docetaxel/osimertinib combinations (20 months).
|
||||
References